Abstract

Alternative polyadenylation (APA) is a post-translational modification that occurs during mRNA maturation in humans. Studies suggested that abnormal APA events are associated with the genesis and progression of malignant tumors. Here, we aimed to comprehensively evaluate the prognostic value of APA events involved in breast cancer (BC). Both APA events and clinical information for BC patients were downloaded from The Cancer Genome Atlas (TCGA) database to identify prognosis-related APA events in BC. A total of 462 APA events and 374 APA events were shown to be significantly related to overall survival (OS) and relapse-free survival (RFS), respectively, of BC patients. The TCGA set was randomly divided into a training and a test set. Key prognosis-related APA events were selected by LASSO regression to build prediction signatures for OS and RFS by multivariate Cox regression analysis in the training, test, and whole set. BC patients were stratified into high-risk and low-risk groups based on median risk scores. Kaplan–Meier survival analysis demonstrated that low-risk groups had better OS and RFS than high-risk groups in all three sets. The time-dependent receiver operating characteristic (ROC) curves showed that our signatures had a good predictive ability for survival and recurrence for BC patients in all three sets. The independent prognostic indicators-based nomogram model had excellent performance and considerable net benefit for predicting the OS and RFS in BC. A PPI network was constructed between key prognosis and core regulators associated with APA, consisting of 48 nodes and 244 edges. Functional enrichment analysis also revealed their association with RNA processing and RNA synthesis. Collectively, our data indicate that prognostic signatures based on APA events may be powerful prognostic predictors for OS and RFS in BC.

Highlights

  • Breast cancer (BC) is the most common malignant disease worldwide and the second cause of cancer-related deaths in women

  • The APA events data for breast cancer (BC) were obtained from the UCSC Xena Browser1 and corresponding clinical information were downloaded from the The Cancer Genome Atlas (TCGA) data portal2

  • A total of 9869 APA events in 9206 genes were identified in the BC patients, indicating that the great majority of genes have a unique APA event

Read more

Summary

Introduction

Breast cancer (BC) is the most common malignant disease worldwide and the second cause of cancer-related deaths in women. Even though remarkable advancements in therapeutic modalities have been made over the years, such as precise surgery, Alternative Polyadenylation Events for Breast Cancer chemotherapy, radiotherapy, hormonal therapy, and molecular targeting therapy, the average 5-year survival rate for BC is still unsatisfactory due to recurrence and metastasis of advanced-stage tumors (Emens, 2018; Ferlay et al, 2019). Some traditional tumor markers are widely used to assess screening, treatment responses, prognosis, and recurrence. More effective biomarkers are needed to evaluate prognosis and occurrence of BC. Such markers can be identified through the elucidation of the molecular mechanisms underlying BC development and progression

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call